The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 07, 2014

Filed:

Jan. 09, 2009
Applicants:

Josef Bencsik, Boulder, CO (US);

James F. Blake, Boulder, CO (US);

Nicholas C. Kallan, Boulder, CO (US);

Ian S. Mitchell, Boulder, CO (US);

Keith L. Spencer, Boulder, CO (US);

Dengming Xiao, Boulder, CO (US);

Rui Xu, Boulder, CO (US);

Christine Chabot, South San Francisco, CA (US);

Steven DO, South San Francisco, CA (US);

Jun Liang, South San Francisco, CA (US);

Brian Safina, South San Francisco, CA (US);

Birong Zhang, South San Francisco, CA (US);

James Graham, Boulder, CO (US);

Inventors:

Josef Bencsik, Boulder, CO (US);

James F. Blake, Boulder, CO (US);

Nicholas C. Kallan, Boulder, CO (US);

Ian S. Mitchell, Boulder, CO (US);

Keith L. Spencer, Boulder, CO (US);

Dengming Xiao, Boulder, CO (US);

Rui Xu, Boulder, CO (US);

Christine Chabot, South San Francisco, CA (US);

Steven Do, South San Francisco, CA (US);

Jun Liang, South San Francisco, CA (US);

Brian Safina, South San Francisco, CA (US);

Birong Zhang, South San Francisco, CA (US);

James Graham, Boulder, CO (US);

Assignees:

Array BioPharma, Inc., Boulder, CO (US);

Genentech, Inc., South San Francisco, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 239/70 (2006.01); A61K 31/517 (2006.01); A61P 35/00 (2006.01); A61P 29/00 (2006.01); A61P 25/00 (2006.01); A61P 9/00 (2006.01); A61P 15/02 (2006.01); A61P 17/00 (2006.01);
U.S. Cl.
CPC ...
C07D 239/70 (2013.01);
Abstract

The present invention provides a compound and pharmaceutically acceptable salts thereof, comprising the Formula I. Also provided are methods of using the compound of this invention as an AKT protein kinase inhibitor and for the treatment of hyperproliferative diseases such as cancer.


Find Patent Forward Citations

Loading…